Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Mizuho Maintains Neutral on Parker Hannifin, Raises Price Target to $310

Mizuho Maintains Neutral on Parker Hannifin, Raises Price Target to $310

Mizuho analyst Brett Linzey maintains Parker Hannifin (NYSE:PH) with a Neutral and raises the price target from $300 to $310.

byBenzinga Newsdesk

January 13, 2023

1 minute read

Mizuho analyst Brett Linzey maintains Parker Hannifin (NYSE:PH) with a Neutral and raises the price target from $300 to $310.

Dynavax Adjuvant Based COVID-19 Vaccine Lowers The Risk Of Transmission

By Vandana Singh

November 30, 10:10 AM

Clover Biopharmaceuticals Ltd announced that Clinical Infectious Diseases has published additional data from the SPECTRA Phase 2/3 trial that showed the SCB-2019 COVID-19…

DVAX

Barclays Maintains Overweight on Danaher, Raises Price Target to $290

By Benzinga Newsdesk

January 24, 7:22 AM

Barclays analyst Luke Sergott maintains Danaher (NYSE:DHR) with a Overweight and raises the price target from $277 to $290.

DHR

News
Tech

Apple’s Split With Steve-Jobs-Era Legendary Designer Jony Ive Is Now Complete

By Shivdeep Dhaliwal

July 13, 9:00 AM

Apple Inc (NASDAQ: AAPL) has ended the consulting agreement with its former design lead Jony Ive.

AAPL

Yellen Says Treasury Monitoring ‘A Few’ Banks Amid Issues At SVB

By Happy Mohamed

March 10, 11:14 AM

- Bloomberg

SPY

Mizuho Maintains Neutral on Parker Hannifin, Raises Price Target to $310

Related Posts

Dynavax Adjuvant Based COVID-19 Vaccine Lowers The Risk Of Transmission

Barclays Maintains Overweight on Danaher, Raises Price Target to $290

Apple’s Split With Steve-Jobs-Era Legendary Designer Jony Ive Is Now Complete

Yellen Says Treasury Monitoring ‘A Few’ Banks Amid Issues At SVB